Evidence library
452 graded sources. Each links to a short context summary and the original source; full extracted findings live in the research corpus.
| ID | Summary | Grade | Tasks |
|---|---|---|---|
BIB_001 | Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth editi | A | 01, 02, 04, 06 |
BIB_002 | Lo SN, Scolyer RA, Thompson JF. Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas: A Breslow Thickness Cut Point of 0.8 mm Separates H | A | 01, 02, 06 |
BIB_003 | Egger ME, Stevenson M, Bhutiani N, Jordan AC, et al. Should Sentinel Lymph Node Biopsy Be Performed for All T1b Melanomas in the New 8th Edition? J Am | B | 01, 04 |
BIB_004 | Isaksson K, Mikiver R, Eriksson H, Lapins J, et al. Survival in 31,670 patients with thin melanomas: a Swedish population-based study. Br J Dermatol 2 | A | 01, 06 |
BIB_005 | Vecchiato A, Cozzolino C, Del Fiore P, et al. Identifying high-risk features and improving follow-up strategies in thin melanoma: a retrospective coho | B | 01, 06 |
BIB_006 | Savage DJ, Switzer B, Parikh R, et al. Patterns in progression from early-stage melanoma to late-stage melanoma: implications for survivorship follow- | B | 01, 05, 06, 23 |
BIB_007 | Richetta AG, Bottoni U, Paolino G, et al. Thin melanoma and late recurrences: it is never too thin and never too late. Med Oncol 2014;31(8):909. PMID | B | 01, 06 |
BIB_008 | Pescarini E, Spanikova G, Mbaidjol Z, et al. Late Metastatic Melanoma after 25 Years: A Case Report and a Brief Literature Review. Case Rep Surg 2020. | C | 01, 06 |
BIB_009 | Thompson JF, Soong SJ, Balch CM, Gershenwald JE, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis o | A | 01, 04 |
BIB_010 | Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and | A | 01, 04 |
BIB_011 | Sabbatino F, Scognamiglio G, Liguori L, et al. Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma. Front Immunol 2020. PMID 3311 | B | 01 |
BIB_012 | Fidanzi C, Bevilacqua M, D'Erme AM, et al. Mitotic rate as a predictive factor for positive sentinel lymph nodes in pT1 and pT2 melanomas. J Plast Rec | B | 01, 04 |
BIB_013 | Mayhew MM, Tocco EG, Mercante MG, et al. Patterns and Predictors of Sentinel Lymph Node Biopsy Utilization in High- and Low-Risk Thin Melanomas. Ann S | B | 01, 04 |
BIB_014 | Donica WRF, Stephens KR, Philips P, et al. Predictors of SLNB in Thin Melanoma: Understanding the Impact of the AJCC 8th Edition Staging System. J Am | B | 01, 04 |
BIB_015 | Marushchak O, Hazan E, Kriegel DA. Analyzing Controversies in Management and Surveillance of Early-Stage Melanoma. Oncol Ther 2020. PMID 32930972. [Ta | C | 01, 05 |
BIB_016 | Gambra Michel LE, Uña Gorospe J, López Figueroa AL, et al. Disease-Free Survival for Patients with Thin Melanomas according to the AJCC 8th Edition. D | B | 01 |
BIB_017 | Vergara-de la Campa L et al. Prognosis of polypoid melanoma. Melanoma Res 2023. PMID 36866632. [Tasks: 01] Tier: 3 Grade: B Retrieved: 2026-05-06 | B | 01 |
BIB_018 | Yu et al. A pan-cancer analysis of the role of argininosuccinate synthase 1 in human tumors. Front Immunol 2023. PMID 38053661. [Tasks: 01, 13, 15] Ti | B | 01, 13, 15 |
BIB_019 | Sentinel-node positivity in very thin (<0.8 mm) melanoma. Br J Dermatol 2023. PMID 37290803. DOI 10.1093/bjd/ljad195. [Tasks: 01, 04] Tier: 3 Grade: B | B | 01, 04 |
BIB_020 | Risk factors and patterns of recurrence after SLNB for thin melanoma. 2022. PMID 33884478. [Tasks: 01, 06] Tier: 3 Grade: B Retrieved: 2026-05-06 | B | 01, 06 |
BIB_021 | Gontijo JRV, Bittencourt FV, Nelson JH, et al. Thin and in situ melanoma: an update for the dermatologist. An Bras Dermatol 2026. PMID 42066632. [Task | C | 01 |
BIB_022 | Choi et al. From toasted skin to tumors: a retrospective nationwide case-control analysis investigating the link between erythema ab igne and various | B | 08b |
BIB_023 | Miller K, Hurwitz S et al. Erythema Ab Igne and Malignant Transformation to Squamous Cell Carcinoma. Cutis 2021. PMID 33651859. DOI 10.12788/cutis.014 | C | 08b |
BIB_024 | Mohr MR, Scott KA, Pariser RM. Laptop computer-induced hyperpigmentation. Dermatol Online J 2018. PMID 30677807. 25-yr-old man, abdomen, "several hour | C | 08b |
BIB_025 | Botelho LF, Moraes MM, Bolzan A. Laptop computer induced erythema ab igne: a new presentation of an old disease. An Bras Dermatol 2016. PMID 28300902. | C | 08b |
BIB_026 | Levinbook WS, Mallett K, Grant-Kels JM. Laptop computer–associated erythema ab igne. Cutis 2007;80(4):319–320. (The index laptop-EAI case.) [Tasks: 08 | C | 08b |
BIB_027 | Tan S et al. Erythema Ab Igne Caused By Laptop Computer. Open Access Maced J Med Sci 2017. PMID 28785341. DOI 10.3889/oamjms.2017.137. [Tasks: 08b] Ti | C | 08b |
BIB_028 | Working from home during and after COVID-19: watch out for [EAI from laptops]. Br J Gen Pract 2020. PMID 32732210. [Tasks: 08b] Tier: 4 Grade: C Retri | C | 08b |
BIB_029 | Saaiq M, Ashraf B. Melanoma Marjolin's ulcer in the hand: A case report. Int J Surg Case Rep 2019. PMID 31280068. DOI 10.1016/j.ijscr.2019.06.029. Mel | C | 08b |
BIB_030 | Murtaza I et al. Mutational spectrum of conserved regions of TP53 and PTEN genes in Kangri cancer (of the skin) in the Kashmiri population. Mutat Res | B | 08b |
BIB_031 | Pandith AA et al. Impact of codon 72 Arg>Pro SNP in TP53 gene on kangri cancer risk: case control study in Kashmir. Tumour Biol 2012. PMID 22249977. D | B | 08b |
BIB_032 | Bhat MA et al. Polymorphic analysis of MHC-linked HSP70 genes: susceptibility and prognostic implication in Kangri cancer cases of Kashmiri population | B | 08b |
BIB_033 | Fang B et al. 42 °C heat stress pretreatment protects human melanocytes against 308-nm laser-induced DNA damage in vitro. Lasers Med Sci 2020. PMID 32 | D | 08b |
BIB_034 | Arrington JH 3rd, Lockman DS. Thermal keratoses and squamous cell carcinoma in situ associated with erythema ab igne. Arch Dermatol 1979;115(10):1226– | C | 08b |
BIB_035 | Alexandrov LB et al. Signatures of mutational processes in human cancer. Nature 2013;500(7463):415–421. UV signature SBS7 foundational paper. [Tasks: | A | 08b, 15 |
BIB_036 | COSMIC Mutational Signatures database (current v3). https://cancer.sanger.ac.uk/cosmic/signatures. UV signatures SBS7a–d. [Tasks: 08b, 15] Tier: 1 Gra | A | 08b, 15 |
BIB_037 | NotebookCheck thermal review, MacBook Pro 16 M2 Max (2023). https://www.notebookcheck.net/ — surface temperatures under sustained load. [Tasks: 08b] T | C | 08b |
BIB_038 | Apple, MacBook Pro 16-inch (2023) Specifications. https://support.apple.com/en-gb/111927. Chassis 35.57 × 24.81 × 1.68 cm. [Tasks: 08b] Tier: 1 Grade: | C | 08b |
BIB_039 | Patel et al. Use of herbal medication in the perioperative period: Potential adverse drug interactions. J Clin Anesth 2024. PMID 38613937. DOI 10.1016 | B | 13a, 13 |
BIB_040 | Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA 2001;286(2):208–216. PMID 11448284. DOI 10.1001/jama.286.2.208. Canonical p | B | 13a, 13 |
BIB_041 | Wahed et al. Effects of naturopathic medicines on Multiplate and ROTEM: prospective pilot study. BMC Complement Altern Med 2016. PMID 26887420. Swedis | B | 13a |
BIB_042 | AAD 2025 — Management of antithrombotic medications in dermatologic surgery, Part 1. J Am Acad Dermatol 2025. PMID 38735483. DOI 10.1016/j.jaad.2024.0 | B | 13a, 03, 04 |
BIB_043 | Memorial Sloan Kettering About Herbs database. https://www.mskcc.org/cancer-care/integrative-medicine/herbs/. Pages retrieved 2026-05-06: turmeric, as | B | 13a, 13 |
BIB_044 | Garlic-Induced Surgical Bleeding case report. A & A Case Reports 2016. PMID 27782907. DOI 10.1213/XAA.0000000000000403. 12 g/day garlic → intraoperati | C | 13a |
BIB_045 | Kim DC et al. Anticoagulant activities of curcumin and its derivative. BMB Rep 2012. PMID 22531131. DOI 10.5483/bmbrep.2012.45.4.221. Curcumin/BDMC pr | B | 13a, 13 |
BIB_046 | Beckert BW et al. The effect of herbal medicines on platelet function. Plast Reconstr Surg 2007. PMID 18090773. DOI 10.1097/01.prs.0000295972.18570.0b | B | 13a |
BIB_047 | Kitridou RC et al. Short-term, moderate-dosage Vitamin E supplementation may have no effect on platelet aggregation, coagulation, bleeding time. J Sur | B | 13a, 13 |
BIB_048 | Herbal supplements: Facts and myths — talking to your patients about herbal supplements. J Perianesth Nurs 2006. PMID 16935738. DOI 10.1016/j.jopan.20 | C | 13a |
BIB_049 | Le Gal K et al. Antioxidants can increase melanoma metastasis in mice. Sci Transl Med 2015;7(308):308re8. Antioxidants (NAC, Vit E) → increased melano | D | 13a, 13 |
BIB_050 | ASA NPO Practice Guidelines (most recent). American Society of Anesthesiologists. Clear-fluid window: up to 2 h pre-op for elective surgery. [Tasks: 1 | C | 13a, 21 |
BIB_051 | Welch HG, Mazer BL, Adamson AS. The rapid rise in cutaneous melanoma diagnoses. NEJM 2021;384(1):72–79. Overdiagnosis framing. [Tasks: L] Tier: 2 Grad | B | L |
BIB_052 | Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. NEJM 2010;363(8):711–723. PMID 2052599 | A | L, 18 |
BIB_053 | Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab in Untreated Advanced Melanoma. NEJM 2015;373(1):23–34. PMID 2602743 | A | L, 18 |
BIB_054 | Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. NEJM 2015;372(26):2521–2532. PMID 25891173. KEYNOTE-006. | A | L, 18 |
BIB_055 | Chapman PB, Hauschild A, Robert C, et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. NEJM 2011;364(26):2507–2516. PMID 2 | A | L, 18 |
BIB_056 | Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. NEJM 2017;377:1813–1823. COMBI-AD. [ | A | L, 18 |
BIB_057 | Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. NEJM 2018;378:1789–1801. KEYNOTE-054. | A | L, 18 |
BIB_058 | Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. NEJM 2017;377:1824–1835. CheckMat | A | L, 18 |
BIB_059 | Patel SP, Othus M, Chen Y, et al. Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. NEJM 2023;388(9):813–823. PMID 36856617. S | A | L, 17, 18 |
BIB_060 | Khattak A, Weber JS, Meniawy T, et al. Distant Metastasis-Free Survival Results from KEYNOTE-942 Phase 2 mRNA-4157-P201 Trial. J Clin Oncol 2024. mRNA | B | L, 17 |
BIB_061 | Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma. Lancet 2018;392(10151):971–984. PMID 30238891. Comprehensive review. [Tasks: L] Tier: 2 Gra | A | L |
BIB_062 | Shain AH, Bastian BC. From melanocytes to melanomas. Nat Rev Cancer 2016;16(6):345–358. PMID 27125352. Pre-malignant progression model. [Tasks: L] Tie | A | L |
BIB_063 | Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018;359(6382):1350–1355. PMID 29567705. Checkpoint blockade review. [Tas | A | L, 18 |
BIB_064 | The Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. Cell 2015;161(7):1681–1696. PMID 26091043. TCGA SKCM 4-subtype classifi | A | L, 15 |
BIB_065 | Atkins MB et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma. J Clin Oncol 1999;17(7):2105–2116. Historical anch | A | L, 18 |
BIB_066 | Long GV, Swetter SM, Menzies AM, Gershenwald JE, Scolyer RA. Cutaneous melanoma. Nat Rev Dis Primers 2023;9:30. Current comprehensive primer. [Tasks: | A | L |
BIB_067 | Balch CM et al. (eds.). Cutaneous Melanoma. Springer, 6th edition 2020. The field's reference textbook. [Tasks: L] Tier: 1 Grade: A Retrieved: 2026-05 | A | L |
BIB_068 | Riker AI (ed.). Melanoma: A Modern Multidisciplinary Approach. Springer, 2nd edition. Alternative reference text. [Tasks: L] Tier: 1 Grade: B Retrieve | B | L |
BIB_069 | WHO Classification of Skin Tumours, 5th edition 2023. IARC. Pathological classification reference. [Tasks: L] Tier: 1 Grade: A Retrieved: 2026-05-06 | A | L |
BIB_070 | Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma. Lancet 202 | A | L, 17 |
BIB_071 | Eroglu Z, Zaretsky JM, Hu-Lieskovan S, et al. High response rate to PD-1 blockade in desmoplastic melanomas. Nature 2018;553:347–350. [Tasks: L] Tier: | A | L |
BIB_072 | Joosse A, Collette S, Suciu S, et al. Sex is an independent prognostic indicator. J Clin Oncol 2013;31(18):2337–2346. [Tasks: L, 06] Tier: 2 Grade: B | B | L, 06 |
BIB_073 | Adamson AS et al. Estimating overdiagnosis of melanoma using trends among Black and White patients in the US. JAMA Dermatol 2022;158:426–431. [Tasks: | B | L |
BIB_074 | Sangers TE et al. SkinVision app validation. Eur J Cancer Prev 2022. Smartphone dermoscopy AI sensitivity / specificity. [Tasks: L] Tier: 3 Grade: B R | B | L |
BIB_075 | Sangers TE et al. Multidiagnostic accuracy of a smartphone app on skin lesion classification. J Eur Acad Dermatol Venereol 2024. [Tasks: L] Tier: 3 Gr | B | L |
BIB_076 | ESMO Patient Guides — Melanoma (multi-language, current edition). https://www.esmo.org/for-patients/patient-guides. [Tasks: L] Tier: 1 Grade: B Retrie | B | L |
BIB_077 | Maggie's Glasgow at Beatson — patient-and-family cancer support centre. https://www.maggies.org/our-centres/maggies-glasgow/ [Tasks: L, 22] Tier: 1 Gr | B | L, 22 |
BIB_078 | Mukherjee S. The Emperor of All Maladies. Scribner 2010. Pulitzer-winning history of oncology. [Tasks: L] Tier: 4 Grade: A Retrieved: 2026-05-06 | A | L |
BIB_079 | Graeber C. The Breakthrough: Immunotherapy and the Race to Cure Cancer. Twelve 2018. Lay-accessible immunotherapy history. [Tasks: L] Tier: 4 Grade: A | A | L |
BIB_080 | Long G & Scolyer R. I Chose to Go to the Edge. (Verify exact title.) Patient-and-physician memoir. [Tasks: L] Tier: 4 Grade: B Retrieved: 2026-05-06 | B | L |
BIB_081 | Routy B et al. Gut microbiome influences efficacy of PD-1-based immunotherapy. Science 2018;359:91–97. [Tasks: L, 11] Tier: 2 Grade: A Retrieved: 2026 | A | L, 11 |
BIB_082 | Gopalakrishnan V et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma. Science 2018;359:97–103. [Tasks: L, 11] Tier: 2 Grad | A | L, 11 |
BIB_083 | Scottish Refugee Council — health navigation and refugee support. https://www.scottishrefugeecouncil.org.uk/ [Tasks: L] Tier: 4 Grade: B Retrieved: 20 | B | L |
BIB_084 | Association of Ukrainians in Great Britain (AUGB), Glasgow branch. https://www.augb.co.uk/ [Tasks: L] Tier: 4 Grade: B Retrieved: 2026-05-06 | B | L |
BIB_085 | Wernham AGH, Tagliaferri L, et al. UK guidelines for the management of cutaneous melanoma 2022. British Journal of Dermatology 2022;187(2):158–167. BA | A | 02 |
BIB_086 | NICE Clinical Guideline NG14 — Melanoma: assessment and management. First published 2015, updated 2022. https://www.nice.org.uk/guidance/ng14 [Tasks: | A | 02, 04, 05, 19a |
BIB_087 | Long GV, Hauschild A, Robert C, et al. Cutaneous melanoma: ESMO CPG for diagnosis, treatment and follow-up. Annals of Oncology 2025. PMID 39550033. [T | A | 02, 04, 05, 18 |
BIB_088 | NCCN Clinical Practice Guidelines in Oncology — Melanoma: Cutaneous. Current version. https://www.nccn.org/guidelines/category1 [Tasks: 02, 04, 05, 18 | A | 02, 04, 05, 18 |
BIB_089 | Williams T et al. Appraisal of International Guidelines for Cutaneous Melanoma Management using the AGREE II assessment tool. JPRAS Open 2022. PMID 35 | B | 02 |
BIB_090 | Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma: comparison of excision with margins of 1 or 3 cm. NEJM 1 | A | 02, 03 |
BIB_091 | Balch CM, Soong SJ, Smith T, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1 | A | 02, 03 |
BIB_092 | Sladden MJ, Balch CM, Barzilai DA, et al. Surgical excision margins for primary cutaneous melanoma. Cochrane Database — current edition. [Tasks: 02, 0 | A | 02, 03 |
BIB_093 | Moncrieff MD et al. MelMarT-II: A randomized trial comparing 1 cm vs 2 cm wide excision margins for primary cutaneous melanoma. ASCO 2023 / 2024. Forw | A | 02, 03 |
BIB_094 | Faries MB, Thompson JF, Cochran AJ, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. NEJM 2017;376(23):2211–2222. | A | 02, 04 |
BIB_095 | Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma | A | 02, 04 |
BIB_096 | Yousef MA et al. Deep Margins Melanoma: How Deep Is Deep Enough? American Surgeon 2023. PMID 36530056. n=385 single-institution retrospective; muscle- | B | 03 |
BIB_097 | Mustela A et al. Silicone sheet/gel for scar management — systematic review. Burns 2014. Supports modest benefit of silicone for scar maturation. [Tas | B | 03, 21 |
BIB_098 | Wong SQ et al. Regional nodal metastasis and 5-year survival in thin melanoma — Queensland population-based. ANZ J Surg 2020. PMID 32162780. n = 4,848 | B | 04 |
BIB_099 | Faries MB et al. Therapeutic Value of SLNB — observation arm regional control. JAMA Surg 2022. PMID 35921122. MSLT-II 10-year follow-up: 80.2 % nodal- | A | 04 |
BIB_100 | Sharon CE et al. Long-term outcomes of nodal surveillance practices in sentinel node positive melanoma: post-MSLT-II cohort. Ann Surg Oncol 2025. PMID | B | 04 |
BIB_101 | Verver D et al. Sensitivity and NPV of SLNB for cutaneous melanoma — meta-analysis. BJS Open 2025. PMID 40810385. Pooled sensitivity 90–95 %; false-ne | A | 04 |
BIB_102 | Bartlett EK et al. Nomograms to Predict Local, Regional, and Distant Recurrence in Thin (T1) Melanomas. J Clin Oncol 2021. PMID 33600211. Dutch + MIA | B | 04, 06 |
BIB_103 | Hessman et al. Is Ultrasound-Based Imaging Essential for Melanoma Active Surveillance? PMID 41400805 (2025). Real-world adherence in SLN-positive coho | B | 05 |
BIB_104 | Janda M et al. 3D Total-Body Photography in Patients at High Risk for Melanoma: A Randomized Clinical Trial. JAMA Dermatology 2025. PMID 40136310. n = | A | 05, 07 |
BIB_105 | Cust AE et al. Cost-Effectiveness Analysis of 3D Total-Body Photography for People at High Risk of Melanoma. PMID 40136266 (2025). [Tasks: 05] Tier: 3 | B | 05 |
BIB_106 | Chen AC et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention (ONTRAC). NEJM 2015;373:1618–1626. Nicotinamide 500 mg BD re | A | 05, 05a, 12 |
BIB_107 | Vecchio TC et al. Management of All Patients with Multiple Actinic Keratoses Requires Lifelong Follow-Up and Repeated Treatment Cycles: A 12-Year Pros | B | 05a |
BIB_108 | Yang TS et al. Comparison of the efficacy of photodynamic therapy and imiquimod cream in patients with actinic keratosis: SR/MA. PMID 41578002 (2026). | A | 05a |
BIB_109 | PDT vs Cryotherapy SR/MA for actinic keratosis. PMID 41964358 (2026). Similar clearance; PDT better cosmesis (RR 1.52). [Tasks: 05a] Tier: 2 Grade: A | A | 05a |
BIB_110 | Bradford PT, Freedman DM, Goldstein AM, Tucker MA. Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol 2010;146(3):2 | A | 07, 05a |
BIB_111 | Khosrotehrani K et al. Second primary invasive cutaneous melanomas in Queensland over 4 decades. PMID 41944800 (2026). n = 101,035; 40-year cumulative | A | 07 |
BIB_112 | Mihm Jr MC, et al. Updated histopathologic criteria for grading melanocytic dysplasia. PMID 39532696 (2026). WHO + Duke approach. [Tasks: 07] Tier: 3 | B | 07 |
BIB_113 | Lesional Markers and Precursors of Melanoma — review. PMID 40581420 (2025). [Tasks: 07, 14] Tier: 3 Grade: B Retrieved: 2026-05-07 | B | 07, 14 |
BIB_114 | Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up (Nambour). J Clin Oncol 2011;29( | A | 08, 05 |
BIB_115 | Bowles HR et al. Facebook Intervention for Young-Onset Melanoma Survivors and Families: RCT Protocol. PMID 36692933 (2023). Behavioural-intervention R | B | 08, 22 |
BIB_116 | O'Neill CM et al. Seasonal Changes in Vitamin D-Effective UVB Availability in Europe. Nutrients 2016. PMID 27589793. Vitamin-D-winter modelling 35–69° | A | 08, 09 |
BIB_117 | IARC Monograph Vol 100D (2012). Ultraviolet radiation including tanning beds — IARC Group 1 carcinogen. [Tasks: 08] Tier: 1 Grade: A Retrieved: 2026-0 | A | 08 |
BIB_118 | Lim L et al. 25-hydroxyvitamin D in resected stage IIB-IIIC melanoma (AVAST-M cohort). Eur J Cancer 2018. PMID 30033445. n = 341; vitamin D level NOT | B | 09 |
BIB_119 | Manson JE, Cook NR, Lee IM, et al. Vitamin D Supplements and Prevention of Cancer and CV Disease (VITAL). NEJM 2019;380(1):33–44. PMID 30415629. n = 2 | A | 09 |
BIB_120 | Burt LA, Billington EO, Rose MS, et al. Effect of High-Dose Vitamin D on BMD: RCT. JAMA 2019;322(8):736–745. PMID 31454046. n = 311, 3-yr; 400 vs 4,00 | A | 09 |
BIB_121 | Hypervitaminosis D and hard-to-heal wounds — case report. 2025. PMID 40358220. 30-year excessive supplementation; soft-tissue calcification + persiste | C | 09 |
BIB_122 | Mooney C et al. Pharmacokinetics of Oral Vitamin D in Children with Obesity and Asthma. PMID 37646988 (2023). Vitamin D PK + BMI relationship. [Tasks: | B | 09 |
BIB_123 | Bolte LA et al. Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma. JAMA Onc | B | 10, 18 |
BIB_124 | Loftfield E et al. Coffee drinking and cutaneous melanoma risk in NIH-AARP. J Natl Cancer Inst 2015. PMID 25604135. n = 447,357 + 2,904 melanomas; ≥ 4 | A | 10 |
BIB_125 | Llaha F et al. Soft drinks + cancer risk SR/MA. PMID 37189146 (2023). +17 % cancer risk per 250 mL/day SSB; low certainty. [Tasks: 10] Tier: 3 Grade: | B | 10 |
BIB_126 | Le Gal K et al. Antioxidants can increase melanoma metastasis in mice. Sci Transl Med 2015. PMID 26446958. NAC + Trolox (vit E analog) → increased lym | A | 10, 13 |
BIB_127 | SU.VI.MAX antioxidant trial post-intervention follow-up. PMID 20605091 (2010). n = 12,741 French; 7.5-yr antioxidant cocktail (vitamin C/E/β-carotene/ | A | 10, 13 |
BIB_128 | Donat-Vargas C et al. Dietary polychlorinated biphenyls and EPA-DHA + melanoma incidence. Eur J Cancer 2017. PMID 28033525. n = 20,785 Swedish women; | B | 10 |
BIB_129 | McQuade JL et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or ch | B | 11, 18 |
BIB_130 | Schmitz KH et al. Exercise is medicine in oncology — ACSM Roundtable cancer-survivor guidelines. CA Cancer J Clin 2019. Recommendations: ≥ 150 min/wk | A | 11, 21 |
BIB_131 | Diaz KM et al. Patterns of Sedentary Behavior and Mortality in U.S. Middle-Aged and Older Adults: A National Cohort Study. Annals of Internal Medicine | A | 11 |
BIB_132 | Liu et al. NLR/PLR/ALB temporal shifts in PD-1 therapy for advanced melanoma. PMID 41561757 (2025). n = 99 advanced melanoma; inflammatory markers pro | B | 11 |
BIB_133 | De Giorgi V et al. Propranolol for Off-label Treatment of Patients With Melanoma: Cohort Study. JAMA Oncology 2018. PMID 28973254. n = 53 PROP + 79 No | B | 12 |
BIB_134 | Liu et al. MBSR in NSCLC patients undergoing surgery and chemotherapy: RCT. PMID 41931358 (2026). n = 80; 8-week MBSR vs standard care; reductions in | B | 12, 22 |
BIB_135 | HCQ + dabrafenib + trametinib trial in BRAF V600 melanoma post-progression. PMID 35377866 (2022). Phase 2; small numbers; rationale autophagy-driven r | B | 12, 18 |
BIB_136 | Phase 1 ADI-PEG 20 (pegargiminase) in ASS1-deficient metastatic uveal melanoma. PMID 35466524 (2022). Direct evidence of arginine-deprivation as thera | B | 13, 15 |
BIB_137 | BCAAs and metabolic enzymes in tumour development — review. Cancer Letters 2026. PMID 41769003. BCAAs activate mTORC1/PI3K/AKT; mixed pro- and anti-tu | C | 13 |
BIB_138 | Isenmann E et al. Ecdysteroids as non-conventional anabolic agent: performance enhancement by ecdysterone supplementation in humans. Arch Toxicol 2019 | B | 13, 13a |
BIB_139 | Gas6/Axl as sensor of arginine-auxotrophic response. PMID 26096933 (2016). Mechanistic: ASS1-negative melanoma cells dependent on extracellular argini | A | 13, 15 |
BIB_140 | AMPK-α1 degradation drives BRAF inhibitor resistance and arginine-deprivation sensitivity in melanoma. PMID 29094484 (2017). Molecular basis for argin | B | 13, 15, 18 |
BIB_141 | Bishop DT, Demenais F, Goldstein AM et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002;94(12):8 | A | 14 |
BIB_142 | Goldstein AM, Chan M, Harland M et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three conti | A | 14 |
BIB_143 | Begg CB, Orlow I, Hummer AJ et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst 2005;97(20): | A | 14 |
BIB_144 | Wiesner T, Obenauf AC, Murali R et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011;43(10):1018–1021. Identification of | A | 14 |
BIB_145 | Yokoyama S, Woods SL, Boyle GM et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011;480(7375):99–103. | A | 14 |
BIB_146 | Robles-Espinoza CD, Harland M, Ramsay AJ et al. POT1 loss-of-function variants predispose to familial melanoma. Nat Genet 2014;46(5):478–481. POT1 tel | A | 14 |
BIB_147 | Concordat and Moratorium on Genetics and Insurance. HM Government + Association of British Insurers. URL: gov.uk/government/publications/code-on-genet | N/A | 14 |
BIB_148 | CAPS Consortium International Consensus for pancreatic cancer surveillance in high-risk individuals. Gut 2020;69(1):7–17. CDKN2A surveillance protocol | A | 14 |
BIB_149 | NHS Scotland Clinical Genetics Services — referral criteria. nhsinform.scot. West of Scotland service at Queen Elizabeth University Hospital, Glasgow; | N/A | 14, 19 |
BIB_150 | COSMIC Catalogue of Somatic Mutations in Cancer — SBS signatures v3.4. sanger.ac.uk/COSMIC. SBS7a-d UV-signature definitions; reference for mutational | N/A | 15, 08b |
BIB_151 | Alexandrov LB, Kim J, Haradhvala NJ et al. The repertoire of mutational signatures in human cancer. Nature 2020;578(7793):94–101. PMID 32025018. Found | A | 15 |
BIB_152 | Hayward NK, Wilmott JS, Waddell N et al. Whole-genome landscapes of major melanoma subtypes. Nature 2017;545(7653):175–180. PMID 28467829. Genomic lan | A | 15 |
BIB_153 | Gerami P et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. J Am Acad Der | B | 15 |
BIB_154 | Royal College of Pathologists. Retention and storage of pathological records and specimens (5th edition + updates). FFPE blocks 30-year minimum; slide | N/A | 15, 24 |
BIB_155 | ClinicalTrials.gov v2 API. clinicaltrials.gov/api/v2/studies. Primary trial-registry source for live UK and EU enumeration. Retrieved 2026-05-07. [Tas | N/A | 16, 17 |
BIB_156 | NCT03860883 MelMarT-II — Melanoma Margins Trial-II. Sponsor: Melanoma & Skin Cancer Trials Ltd. 1 cm vs 2 cm WLE margin for Stage II primary cutaneous | A | 16, 03 |
BIB_157 | NCT05727904 TILVANCE-301 — lifileucel + pembrolizumab vs pembrolizumab in advanced unresectable melanoma. Phase III. Iovance Biotherapeutics. 6 UK sit | A | 16, 17, 18 |
BIB_158 | NCT06112314 PRISM-MEL-301 — IMC-F106C (PRAME-targeted bispecific TCE) vs nivolumab regimens in 1L advanced melanoma. Phase III. Immunocore Ltd. 8 UK s | A | 16, 17, 18 |
BIB_159 | DETERMINE umbrella trial — Cancer Research UK rare-cancer trial platform. NCT05770102 (atezolizumab arm), NCT05770544 (entrectinib arm), NCT05768178 ( | A | 16, 17 |
BIB_160 | NCT07049276 MSLT-3 — Multicentre Selective Lymphadenectomy Trial 3. Stage III post-positive-SLN management strategies. Melanoma Institute Australia + | A | 16, 18 |
BIB_161 | NHS Scotland Genomic Medicine Service (GeMS). NHS England Genomic Medicine Service Cancer arm offers WGS for Stage IV melanoma at commissioned centres | N/A | 14, 15, 16 |
BIB_162 | Long GV et al. Adjuvant pembrolizumab vs placebo in resected stage IIB/IIC melanoma (KEYNOTE-716): randomised, double-blind, phase 3 trial. Lancet 202 | A | 17, 18 |
BIB_163 | Kirkwood JM et al. Adjuvant nivolumab vs placebo in resected stage IIB/IIC melanoma (CheckMate-76K): phase 3 RCT. Nature Medicine 2024. n=790; RFS HR | A | 17, 18 |
BIB_164 | Khattak A et al. Distant metastasis-free survival with adjuvant mRNA-4157 (V940) + pembrolizumab vs pembrolizumab alone in resected high-risk melanoma | A | 17, 18 |
BIB_165 | INTerpath-001 / V940-002 (NCT05933577). Phase III mRNA-4157 (V940) + pembro vs pembro in resected Stage IIB-IV melanoma. ~1,089 enrolled; primary endp | A | 17, 18 |
BIB_166 | Patel SP et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma (SWOG S1801). NEJM 2023;388(9):813–823. PMID 36856617. n=313 | A | 17, 18 |
BIB_167 | Blank CU et al. Neoadjuvant nivolumab + ipilimumab vs adjuvant nivolumab in macroscopic stage III melanoma (NADINA). NEJM 2024;391(18):1696–1708. PMID | A | 17, 18 |
BIB_168 | Sarnaik AA et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J Clin Oncol 2021;39(24):2656–2666 + 2024 follow-up. PM | A | 17, 18, 19a |
BIB_169 | Routy B et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018;359(6371):91–97. PMID 29097494. | B | 17, 11 |
BIB_170 | Davar D et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma. Science 2021;371(6529):595–602. PMID 33542131. ~30% | B | 17 |
BIB_171 | Tawbi HA et al. Relatlimab + nivolumab vs nivolumab alone in untreated advanced melanoma (RELATIVITY-047). NEJM 2022;386(1):24–34. PMID 34986285. LAG- | A | 17, 18 |
BIB_172 | Carvajal RD / Nathan P et al. Tebentafusp (gp100×CD3 BiTE) in untreated metastatic uveal melanoma. NEJM 2021;385(13):1196–1206. PMID 34551219. First s | A | 17, 18 |
BIB_173 | Eggermont AMM et al. Adjuvant Pembrolizumab vs Placebo in Resected Stage III Melanoma (KEYNOTE-054). NEJM 2018;378(19):1789–1801. PMID 29658430. Stage | A | 18, 17 |
BIB_174 | Weber JS et al. Adjuvant Nivolumab vs Ipilimumab in Resected Stage III/IV Melanoma (CheckMate-238). NEJM 2017;377(19):1824–1835. PMID 28891423. RFS HR | A | 18 |
BIB_175 | Long GV et al. Adjuvant Dabrafenib + Trametinib in Stage III BRAF-Mutated Melanoma (COMBI-AD). NEJM 2017;377(19):1813–1823. PMID 28891408. RFS HR 0.51 | A | 18 |
BIB_176 | Robert C et al. Pembrolizumab vs Ipilimumab in Advanced Melanoma — 5-year follow-up (KEYNOTE-006). Lancet Oncology 2019;20(9):1239–1251. PMID 31345627 | A | 18 |
BIB_177 | Long GV / Robert C et al. Dabrafenib + Trametinib in BRAF V600-mutant metastatic melanoma (COMBI-d, COMBI-v). Lancet 2014/NEJM 2014. Combined PFS ~11 | A | 18 |
BIB_178 | Dummer R et al. Encorafenib + Binimetinib (COLUMBUS). Lancet Oncology 2018;19(5):603–615. PMID 29602646. PFS ~14 months; ORR ~64%; OS ~33 months. Bett | A | 18 |
BIB_179 | Larkin J et al. Vemurafenib + Cobimetinib (coBRIM). NEJM 2014;371(20):1867–1876. PMID 25265492. PFS ~12 months; ORR ~70%. Photosensitivity + dermatolo | A | 18 |
BIB_180 | Atkins MB et al. DREAMseq — Sequential Therapy in BRAF V600 Mutant Metastatic Melanoma. J Clin Oncol 2023;41(2):186–197. PMID 36166727. Establishes IC | A | 18 |
BIB_181 | Tawbi HA et al. Combined Nivolumab + Ipilimumab in Melanoma Metastatic to the Brain (CheckMate-204). NEJM 2018;379(8):722–730. PMID 30134131. Intracra | A | 18 |
BIB_182 | Long GV et al. Combination nivolumab + ipilimumab vs nivolumab alone in melanoma brain metastases (ABC trial). Lancet Oncology 2018;19(5):672–681. PMI | A | 18 |
BIB_183 | Wolchok JD et al. 10-year OS outcomes in metastatic melanoma treated with nivolumab + ipilimumab or nivolumab alone (CheckMate-067 follow-up). NEJM 20 | A | 18 |
BIB_184 | Beatson West of Scotland Cancer Centre — NHS GG&C public information; melanoma MDT at QEUH Glasgow campus; West Scotland regional cancer centre. (Veri | N/A | 19, 16, 18 |
BIB_185 | Royal Marsden Hospital Melanoma Service. ICR-affiliated; Larkin (clinical lead), Turajlic (translational), broader oncology team. International + UK r | N/A | 19, 16, 18 |
BIB_186 | Melanoma Institute Australia (MIA), Sydney. Virtual MDT international second-opinion service ~AUD 2,000–3,000; Long, Scolyer, Thompson, Spillane leade | N/A | 19 |
BIB_187 | Memorial Sloan Kettering Virtual Second Opinion service. $1,500–$3,000 USD; 1–4 weeks; pathology re-read included. mskcc.org. (Verified 2026-05-07.) [ | N/A | 19 |
BIB_188 | 21st Century Cures Act, US Public Law 114-255, signed December 2016. Established Cancer Moonshot funding ~$1.8B over 7 years; companion to original 20 | N/A | 19 |
BIB_189 | Biden Cancer Initiative. Founded 2017 by Joe + Jill Biden post-vice-presidency; Greg Simon as president. Suspended April 2019 ahead of presidential ca | N/A | 19 |
BIB_190 | Cancer Moonshot Reignition, February 2022. White House public statements + executive memoranda; goal to halve US cancer death rates over 25 years. whi | N/A | 19 |
BIB_191 | Maggie's Centres Scotland — Glasgow (next to Beatson QEUH) + Edinburgh (Western General). Free drop-in cancer support; multilingual interpreter access | N/A | 11, 12, 19, 22 |
BIB_192 | NHS Greater Glasgow & Clyde Cancer Network — public commissioning information; melanoma MDT routing from dermatology → Beatson MDT. (Verified 2026-05- | N/A | 19, 20 |
BIB_193 | NICE National Institute for Health and Care Excellence. Technology Appraisals catalogue. nice.org.uk. Statutory body for England + Wales; TAs mandator | N/A | 19a |
BIB_194 | Scottish Medicines Consortium (SMC). Published-advice catalogue. scottishmedicines.org.uk. Binding for NHS Scotland; advice IDs (e.g. SMC2425). (Verif | N/A | 19a |
BIB_195 | NICE TA766 — Pembrolizumab for adjuvant treatment of completely resected stage III melanoma. 2022. NHS England standard adjuvant route. [Tasks: 19a, 1 | N/A | 19a, 18 |
BIB_196 | NICE TA837 — Pembrolizumab for adjuvant treatment of completely resected stage IIB or IIC melanoma. 2022. KEYNOTE-716 evidence basis. [Tasks: 19a, 18] | N/A | 19a, 18 |
BIB_197 | NICE TA744 — Nivolumab + ipilimumab for previously untreated advanced melanoma. 2021. CheckMate-067 evidence basis. [Tasks: 19a, 18] Tier: 2 Grade: N/ | N/A | 19a, 18 |
BIB_198 | NICE TA544 — Adjuvant dabrafenib + trametinib for resected BRAF V600 mutation-positive stage III melanoma. 2018. COMBI-AD evidence basis. [Tasks: 19a, | N/A | 19a, 18 |
BIB_199 | NICE TA396 — Dabrafenib + trametinib for previously untreated unresectable / metastatic BRAF V600 melanoma. 2016 + updates. COMBI-d/v evidence basis. | N/A | 19a, 18 |
BIB_200 | NICE TA562 — Encorafenib + binimetinib for previously untreated unresectable / metastatic BRAF V600 melanoma. 2019. COLUMBUS evidence basis. [Tasks: 1 | N/A | 19a, 18 |
BIB_201 | NICE TA410 — Talimogene laherparepvec (T-VEC) for unresectable Stage IIIB-IVM1a melanoma. 2016. Intralesional oncolytic. [Tasks: 19a, 18] Tier: 2 Grad | N/A | 19a, 18 |
BIB_202 | NHS Scotland Cancer Drugs Fund. Separate from NHS England CDF; covers some drugs in Scotland that NHS commissioning hasn't yet picked up. gov.scot. (V | N/A | 19a, 20 |
BIB_203 | MHRA Early Access to Medicines Scheme (EAMS). gov.uk/guidance/apply-for-the-early-access-to-medicines-scheme-eams. Designation for unmet-need pre-lice | N/A | 19a, 20 |
BIB_204 | NHS Greater Glasgow & Clyde Local Formulary. Internal commissioning route; public summary at nhsggc.scot. Local Decision Making (LDM) committee overse | N/A | 19a, 20 |
BIB_205 | UK General Data Protection Regulation (UK GDPR) + Data Protection Act 2018. Patient access rights to medical records (Subject Access Requests); free + | N/A | 20 |
BIB_206 | NHS Greater Glasgow & Clyde Subject Access Request process. nhsggc.scot. Standard SAR submission procedure; free of charge per UK GDPR. (Verified 2026 | N/A | 20 |
BIB_207 | NHS Scotland Patient Online / NHS Inform Scotland. nhsinform.scot. Patient-facing information portal; appointment + correspondence access varies by re | N/A | 20 |
BIB_208 | Global Health Insurance Card (GHIC). UK government EHIC successor post-Brexit. gov.uk/global-health-insurance-card. Covers state-equivalent EU/EFTA ca | N/A | 20, 21 |
BIB_209 | UK specialist cancer travel insurance providers (CoverForYou, AllClear, InsureCancer; broker-aggregator overview). Cancer-declared travel cover; typic | N/A | 20, 21 |
BIB_210 | Ukrainian Family Scheme / Homes for Ukraine. gov.uk/guidance/apply-for-a-ukraine-family-scheme-visa. Ukrainian refugees on these schemes have full NHS | N/A | 20 |
BIB_211 | Mustelin SO et al. Topical silicone gel for the prevention and treatment of hypertrophic scar and keloid: A systematic review. Burns 2014. Foundationa | B | 21 |
BIB_212 | International Society for Burn Injuries (ISBI) Practice Guidelines for burn care 2014. Silicone gel/sheet guidance; applicable to surgical scars. [Tas | N/A | 21 |
BIB_213 | NICE NG89. Venous thromboembolism in over 16s: reducing the risk in hospital and during travel. nice.org.uk. (Verified 2026-05-07.) [Tasks: 21] Tier: | A | 21 |
BIB_214 | British Thoracic Society + ACCP guidelines on travel-associated venous thromboembolism. brit-thoracic.org.uk + chestnet.org. (Verified 2026-05-07.) [T | A | 21 |
BIB_215 | NHS Inform Scotland — wound care + surgical recovery + post-op information. nhsinform.scot. (Verified 2026-05-07.) [Tasks: 20, 21] Tier: 2 (NHS) Grade | N/A | 20, 21 |
BIB_216 | Bray J et al. Postoperative care after wide local excision in melanoma — practice guidance review. J Plast Reconstr Aesthet Surg (year + PMID to verif | B | 21, 03 |
BIB_217 | Faller H et al. Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review a | A | 22, 12 |
BIB_218 | Hulbert-Williams NJ et al. Acceptance and commitment therapy (ACT) for cancer-related distress: systematic review and meta-analysis. Eur J Cancer Care | B | 22 |
BIB_219 | Smith AB et al. Conquer Fear: phase II RCT of an intervention for fear of cancer recurrence. J Clin Oncol 2019;37(31):2823–2832. RCT-grade FCR-specifi | A | 22 |
BIB_220 | Lebel S et al. Fear of Cancer Recurrence: A meta-analytic review. Psycho-Oncology 2018. Foundational FCR construct + measurement literature. [Tasks: 2 | A | 22 |
BIB_221 | Mustafa M et al. Psychological interventions for women with breast cancer (Cochrane review). Cochrane Database 2013. PMID 23797679. Methodology applic | A | 22 |
BIB_222 | NICE NG134. Depression in adults: treatment and management. nice.org.uk. (Verified 2026-05-07.) [Tasks: 22] Tier: 1 (UK guideline) Grade: A Retrieved: | A | 22 |
BIB_223 | NICE NG113. Generalised anxiety disorder + panic disorder in adults: management. nice.org.uk. (Verified 2026-05-07.) [Tasks: 22] Tier: 1 Grade: A Retr | A | 22 |
BIB_224 | NICE NG144. Post-traumatic stress disorder: recognition and treatment. nice.org.uk. Relevant for war-refugee context. (Verified 2026-05-07.) [Tasks: 2 | A | 22 |
BIB_225 | Macmillan Cancer Support 2024 Annual Report. UK cancer-care psychosocial impact data; phone-line statistics; financial-support service overview. macmi | N/A | 22, 20 |
BIB_226 | Samaritans UK. 24/7 listening service 116 123. samaritans.org. (Verified 2026-05-07.) [Tasks: 22] Tier: 4 (charity) Grade: N/A Retrieved: 2026-05-07 | N/A | 22 |
BIB_227 | Mind UK mental-health charity. mind.org.uk. Helpline 0300 123 3393. (Verified 2026-05-07.) [Tasks: 22] Tier: 4 (charity) Grade: N/A Retrieved: 2026-05 | N/A | 22 |
BIB_228 | The Cancer Genome Atlas (TCGA) / Genomic Data Commons (GDC). NIH cancer-genomics public dataset; portal.gdc.cancer.gov. TCGA-SKCM Skin Cutaneous Melan | N/A | 22a, 15 |
BIB_229 | cBioPortal for Cancer Genomics. Web-based aggregator of public cancer-genomics datasets. cbioportal.org. (Verified 2026-05-07.) [Tasks: 22a] Tier: 1 ( | N/A | 22a |
BIB_230 | Genomics England Research Network. UK 100,000 Genomes Project successor; Discovery Forum research access. genomicsengland.co.uk. (Verified 2026-05-07. | N/A | 22a, 14, 15 |
BIB_231 | Cancer Grand Challenges (CRUK + NCI joint). Team-science cancer research funding. grandchallenge.cancer.org.uk. (Verified 2026-05-07.) [Tasks: 22a, 19 | N/A | 22a, 19 |
BIB_232 | AACR Project GENIE. International clinical cancer-genomics consortium; ~150,000+ patients across MSK, Dana-Farber, Vanderbilt, MD Anderson, Royal Mars | N/A | 22a |
BIB_233 | DepMap. Broad Institute cancer cell-line dependency dataset; 1,000+ cell lines profiled. depmap.org. (Verified 2026-05-07.) [Tasks: 22a] Tier: 2 (rese | N/A | 22a |
BIB_234 | NCI Cancer Moonshot Bio-data Catalyst. NCI federated data infrastructure for cancer research; cloud-based analysis. biodatacatalyst.nhlbi.nih.gov. (Ve | N/A | 22a, 19 |
BIB_235 | GenoMEL Consortium. International collaborative on inherited melanoma genetics; family-cohort registries. genomel.org. (Verified 2026-05-07.) [Tasks: | N/A | 22a, 14 |
BIB_236 | Jumper J et al. (DeepMind). Highly accurate protein structure prediction with AlphaFold. Nature 2021;596(7873):583–589. PMID 34265844. Foundational pr | A | 22a |
BIB_237 | Cheng J et al. (DeepMind). Accurate proteome-wide missense variant effect prediction with AlphaMissense. Science 2023;381(6664). PMID 37733851. Genome | A | 22a, 14 |
BIB_238 | Commercial pathology AI platforms — PathAI, Paige.AI, Visiopharm, Owkin. (Cross-link TASK17 §17.6.) (Verified 2026-05-07.) [Tasks: 22a, 17] Tier: 3 (c | N/A | 22a, 17 |
BIB_239 | Public bioinformatics + computational-biology courses: Coursera Genomic Data Science (Johns Hopkins); MIT 7.91J/20.490J open-access; Harvard HMS HST s | N/A | 22a |
BIB_240 | Wevers KP et al. Surveillance adherence and outcome in melanoma — cohort analysis. PMID + year to verify at retrieval. Surveillance-adherence vs LTS c | B | 23, 5 |
BIB_241 | CaringBridge memorialised journals + Melanoma Focus + Melanoma UK + AIM at Melanoma + Melanoma Research Foundation patient narrative archives. Qualita | N/A | 23, 22 |
BIB_242 | NHS NCRAS (National Cancer Registration and Analysis Service). UK population mortality + cancer-incidence data. ncras.nhs.uk / publichealth.org.uk. (V | N/A | 23, 6 |
BIB_243 | EUROCARE European cancer-mortality database. Population-based 5-yr survival comparisons across European countries. eurocare.it. (Verified 2026-05-07.) | N/A | 23, 6 |
BIB_244 | NHSScotland Cutaneous Melanoma National Follow-Up Guideline v1.0 (West of Scotland Cancer Network / WoSCAN; endorsed across Scotland regional networks | A | 05, 25 |
BIB_245 | Right Decisions Scotland (Healthcare Improvement Scotland) — Cutaneous melanoma (SIGN) toolkit, Follow-up page. https://rightdecisions.scot.nhs.uk/cut | A | 05, 25 |
BIB_246 | NICE NG14 Melanoma: assessment and management. Follow-up section (Stage IB: Y1 = 2 clinic appointments; Y2–3 = 1/year; Y4–5 = 1/year; discharge end Y5 | A | 02, 04, 05 |
BIB_247 | Sten Ekberg DC (Wellness For Life, Cumming GA). YouTube channel "Dr. Ekberg" (~3M+ subscribers as of 2026; verified via youtube.com/@DrEkberg). Source | D | 10, 12, 13, 22 |
BIB_248 | Weller RB | B | 08, 09, 11 |
BIB_249 | NCT06896552 — "Single-Center Trial on Ketogenic Diet and Immunotherapy" (clinicaltrials.gov/study/NCT06896552). 2024-registered trial evaluating ketog | N/A | 10, 16, 17 |
BIB_250 | Helvind NM, Brinch-Møller Weitemeyer M, Chakera AH, et al. | A | 06, 17, 23, 24a |
BIB_251 | Woodford R, Lorigan P, Oudit D, Abdulgawad A, Thistlethwaite F, Lim KHJ. | B | 17, 18, 19, 19a |
BIB_252 | Perkin P, Köş FT. | C | 17, 18, 24a |
BIB_253 | NICE GID-TA10752 — Lifileucel for previously treated unresectable or metastatic melanoma. | A | 17, 18, 19a |
BIB_254 | Maggie's Glasgow (Gartnavel General Hospital campus). | A | 11, 19, 22 |
BIB_255 | NHS Inform Scotland — Russian-language translation portal for displaced persons from Ukraine. | A | 11, 20, 22, 24 |
BIB_256 | BAD Patient Information Leaflet — Melanoma Stage 1B. | B | 01, 02, 03, 04, 05, 09, 14 |
BIB_257 | Melanoma Focus — Wide Local Excision patient guide. | B | 03, 21 |
BIB_258 | DermNet NZ — Dermoscopy Pattern Analysis. | B | 04, 07, 24, 24a |
BIB_259 | McCormack T, Wickham A, McDonagh STJ, Wiles MD, Faconti L, Brooks R, Anderson SG, Hartle A. | A | 13a, 24, BRIEF §4.6 |
BIB_260 | Yoon CH, Ross MI, Gastman BR, Luke JJ, Ascierto PA, Long GV, et al. | A | 17, 18, 24a |
BIB_261 | Leachman SA et al. | A | 05a, 17, 18, 24a |
BIB_262 | Moderna/Merck KEYNOTE-942 5-year follow-up of mRNA-4157 (V940/intismeran autogene) + pembrolizumab in resected Stage III/IV melanoma. | B | 17, 18, 22a |
BIB_263 | NHS Cancer Vaccine Launch Pad (CVLP) — Melanoma trial pipeline status May 2025-2026. | A | 17, 19a |
BIB_264 | Beatson West of Scotland Cancer Centre — Clinical Trials Unit, NRS Cancer-West. | A | 16, 19 |
BIB_265 | ASCO 2026 Annual Meeting — timing relevant to patient's recovery window. | N/A | 16, 17 |
BIB_266 | Patidar V, Hall MAK, Cruser B. | C | 08b, 24 |
BIB_267 | Leachman SA, Luke JJ, Ascierto PA, Long GV, Khattak MA, Rutkowski P, Xu ZJ, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Schadendorf D. | A | 05a, 17, 18, 24a |
BIB_268 | Pierpont YN, Dinh TP, Salas RE, et al. | B | 11, 21 |
BIB_269 | Yi Y, et al. | B | 10, 21 |
BIB_270 | Boydell E, Borgeaud M, Tsantoulis P. | B | 06, 17, 23 |
BIB_271 | CDC Travelers' Health — Blood Clots During Travel. | A | 11, 21 |
BIB_272 | NHSGGC Inverclyde Royal Hospital Site Map. | N/A | 24 |
BIB_273 | Ansstas G, Khaddour K, Sudhaman S, et al. | A | 05, 06, 17, 24, 24a |
BIB_274 | NHS Greater Glasgow & Clyde — Subject Access Request (Living Records) Process. | A | 20, 24 |
BIB_275 | Association of British Insurers (ABI) — Code on Genetic Testing and Insurance, March 2026 update. | A | 14, 20 |
BIB_276 | Melanoma Research Alliance patient narrative — Leah Adams. | N/A | 22, 23 |
BIB_277 | ASCO 2026 Annual Meeting — Melanoma/Skin Cancers Oral Abstract Session: Abstract 9501. | C | 17 |
BIB_278 | Beatson West of Scotland Cancer Centre — Skin Cancer Team contacts. | A | 19, 20, 24, BRIEF §4.11 |
BIB_279 | Macmillan Cancer Support — Russian translations library + Support Line interpreter service. | A | 11, 20, 22, 24 |
BIB_280 | Scottish Government — Scottish Referral Guidelines for Suspected Cancer 2025. | A | 02, 19, 20, 24 |
BIB_281 | Lyhne JD et al. | B | 22 |
BIB_282 | Amaral T, Ottaviano M, Arance A, Blank C, ...Lorigan P, ...Ascierto PA; ESMO Guidelines Committee. | A | 02, 03, 04, 05, 17, 18 |
BIB_283 | Xie J, Kiuru M, Pollock BH, Keegan THM. | A | 06, 07, 23 |
BIB_284 | Soyer HP, Jayasinghe D, Rodriguez-Acevedo AJ, ...Janda M. | A | 05, 07, 14 |
BIB_285 | Cebolla-Verdugo M et al. | B | 07, 14 |
BIB_286 | NHS Inform Scotland — Healthcare for refugees and asylum seekers. | A | 11, 20, 22, BRIEF §4.10 |
BIB_287 | Scottish Refugee Council — Information for Ukrainian guests and hosts. | A | 11, 22, BRIEF §4.9/§4.10 |
BIB_288 | Lviv Oncology Regional Treatment and Diagnostic Center, Ukraine — culturally-connected secondary option. | B | 19, 22 |
BIB_289 | Ukraine national melanoma policy update — immunotherapy coverage starting June 2026. | B | 19, 22 |
BIB_290 | Helgadottir H, Mikiver R, Schultz K, Nielsen K, Portelli F, Lapins J, Puig S, Isaksson K. | A | 06, 23 |
BIB_291 | Sheba Medical Center (Tel HaShomer, Israel) — Ella Lemelbaum Institute for Immuno-Oncology and Melanoma. | B | 17, 18, 19 |
BIB_292 | Princess Margaret Cancer Centre (Toronto, Canada) — Clinical Trials Unit (CCRU). | B | 19 |
BIB_293 | MISS (Melanoma in Southern Sweden) cohort — Lund University. | A | 08, 09, 11 |
BIB_294 | CHINA — Peking University Cancer Hospital and Institute, Beijing. | B | 17, 18, 19 |
BIB_295 | RUSSIA — "Neovac RONTS" personalized mRNA melanoma vaccine. | C | 17, 19 |
BIB_296 | CheckMate 067 — 10-YEAR FOLLOW-UP — NEJM 2024 Sept 15. LANDMARK PAPER. | A | 17, 18, 23 |
BIB_297 | USA — MD Anderson Cancer Center, Department of Melanoma Medical Oncology. | A | 17, 18, 19 |
BIB_298 | USA — Dana-Farber Cancer Institute, 2026 Cancer Research Breakthroughs Roundup. | A | 17, 18, 19 |
BIB_299 | UKRAINE — National Cancer Registry of Ukraine (NCRU) Bulletin Vol. 25 — Cancer in Ukraine 2022-2023. | A | 19, 22 |
BIB_300 | Bhave P, et al. Clinical and pathological characteristics of thin cutaneous melanoma with very late recurrence. | B | 05, 06, 23, 24a, 25 |
BIB_301 | ASCO 2026 Annual Meeting — CORRECTED abstract embargo dates. | N/A | 16, 17 |
BIB_302 | Slavic / Eastern European CDKN2A founder variants — relevant to Ukrainian-ancestry genetic testing. | B | 14 |
BIB_303 | Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw — POLAND. | A | 19 |
BIB_304 | Melanoma UK patient stories archive — survivor narratives. | B | 22, 23 |
BIB_305 | Melanoma Focus patient stories archive — survivor + non-survivor narratives. | B | 22, 23 |
BIB_306 | Jimmy Carter melanoma case — the headline immunotherapy success narrative. | B | 18, 22, 23 |
BIB_307 | NHS England + NICE HTE24 — DERM AI dermatology technology conditionally approved for NHS use. | A | 05, 17 |
BIB_308 | Cancer Research UK — Family-member skin screening criteria for higher-than-average risk. | A | 05, 14, 22, 22a |
BIB_309 | Mederle AL et al. Teledermatology and Teledermoscopy for Melanoma Care. | B | 05, 17 |
BIB_310 | Tung KM, Su Y, Kang YN, Hou WH, Hoang KD, Chen KH, Chen C. | A | 22, 24 |
BIB_311 | Castaño-Asins JR, Barceló-Soler A, et al. | A | 22, 24 |
BIB_312 | Hall AE, Nguyen NH, Cascavita CT, Shariati K, et al. | A | 22, 24 |
BIB_313 | WoSCAN — West of Scotland Cancer Network Skin Cancer MCN Reports of the Melanoma Clinical Audit Data (annual). | A | 02, 05, 19, 20 |
BIB_314 | Macmillan Cancer Support — Multidisciplinary Team (MDT) for melanoma. | A | 19, 20, 22 |
BIB_315 | CheckMate 238 — 9-year follow-up — ESMO Congress November 2025 + 2024 ESMO update. | A | 17, 18 |
BIB_316 | ESMO Congress 2026 — annual European oncology meeting. | N/A | 16, 17 |
BIB_317 | NICE GID-TA10752 (Lifileucel) — UPDATED TIMELINE (verified 2026-05-14 via rag-browser direct fetch). | A | 17, 19a |
BIB_318 | WoSCAN 2022 — Surveillance imaging radiation risk numbers (NEW content extracted via rag-browser PDF fetcher 2026-05-14). | A | 05, 17, 24a |
BIB_319 | WoSCAN 2022 — Holistic Needs Assessment (HNA) mandate + Appendix 1 scoring scale + MDT model of care (verbatim from PDF 2026-05-14). | A | 05, 19, 20, 22, 24 |
BIB_320 | Reijers ILM, Menzies AM, van Akkooi ACJ, Versluis JM, et al. (Blank C, Long G, MIA Sydney + NKI Amsterdam + multicentre). NADINA trial: Neoadjuvant ni | A | 18, 19, 19b |
BIB_321 | Reijers ILM, Blank CU et al. PRADO trial 5-year survival + biomarker analysis: neoadjuvant ipilimumab plus nivolumab in stage III macroscopic melanoma | A | 18, 19, 19b |
BIB_322 | Ribas A et al. (UCLA + multicentre). AMBER cohorts 1c/1e/2A: Combined PD-1 and TIM-3 targeting (cobolimab + dostarlimab) in locally advanced or metast | B | 17, 18, 19b |
BIB_323 | Ribas A et al. (UCLA + SWOG cooperative group). SWOG S1512: Phase 2 anti-PD-1 in unresectable desmoplastic melanoma. Nat Med November 2025. Key number | A | 01, 18, 19b |
BIB_324 | Schadendorf D et al. (Essen + multicentre). RELATIVITY-098: Adjuvant nivolumab plus relatlimab vs nivolumab alone in stage III/IV resected melanoma. P | A | 17, 18, 19b |
BIB_325 | Schadendorf D, Long GV et al. COMBI-AD ctDNA biomarker analysis: BRAFV600 ctDNA as prognostic marker in resected stage III melanoma receiving adjuvant | B | 06, 15, 17, 19b |
BIB_326 | Hassel JC et al. (NCT Heidelberg + multicentre). Tebentafusp T-cell engager in uveal melanoma — Phase III long-term update. NEJM 2024-2025. The single | A | 18, 19b |
BIB_327 | Khattak A, Weber JS, Long GV, Schadendorf D, Carlino MS et al. (Mainz/BioNTech + Moderna + multicentre). KEYNOTE-942 5-year update: intismeran autogen | A | 17, 18, 19b |
BIB_328 | Robert C et al. (Gustave Roussy + Paris-Saclay + multicentre). KEYNOTE-006 10-year follow-up: pembrolizumab vs ipilimumab in stage IV melanoma. ESMO 2 | A | 18, 19b, 22, 23, 25 |
BIB_329 | Gaudy-Marqueste C et al. (Aix-Marseille + French multicentre cohort). Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma: rea | B | 17, 19b |
BIB_330 | Garbe C, Eigentler T et al. (Tübingen + EADO). European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2024. E | A | 01, 02, 04, 05, 19b |
BIB_331 | Helgadottir H, Hansson J et al. (Karolinska + Swedish multicentre). NEO-MEL: Neoadjuvant immunotherapy in resectable stage III/IV cutaneous melanoma — | B | 17, 18, 19b |
BIB_332 | Yamazaki N et al. (National Cancer Center Tokyo). Comprehensive epidemiology of melanoma at all sites: insights from Japan's National Cancer Registry, | B | 06, 19b |
BIB_333 | Si L, Wei XW, Bai X, Mao L, Guo J et al. (Peking University Cancer Hospital). CAP 03: Camrelizumab plus apatinib and temozolomide as first-line treatm | B | 17, 18, 19b |
BIB_334 | Schumann J, Dummer R et al. (Zurich + multicentre). Switching PD-1 to BRAF + MEK inhibition in second-course adjuvant melanoma therapy. J Eur Acad Der | B | 17, 18, 19b |
BIB_335 | Lovat P, Roesch A et al. (Newcastle University + AmLo Biosciences). AMBLor — autophagy-based immunohistochemistry prognostic biomarker for Stage IB/II | C | 06, 15, 17, 19b |
BIB_336 | Leachman SA, Ascierto PA, Khattak A, et al. (Oregon Health & Science University + KEYNOTE-716 investigators). KEYNOTE-716 long-term update: nonmelanom | A | 05a, 17, 19b |
BIB_337 | Ideaya Biosciences + multicentre investigators. Optimum-02 phase 3: darovasertib (PKC inhibitor) + crizotinib in metastatic uveal melanoma — positive | A | 17, 18, 19b |
BIB_338 | NICE Lifileucel STA GID-TA10752 — timeline update verified 2026-05-15. | N/A | 17, 19a |
BIB_339 | DETECTION-2 Feasibility study — ISRCTN13695430. | B | 16, 17 |
BIB_340 | Roginolisib Phase II — NCT06717126. | B | 16 |
BIB_341 | Cancer Research UK — "Manchester scientists discover simple blood test to spot skin cancer returning" | B | 16, 17 |
BIB_342 | NORMA-2 — NCT07530887. | A | 03, 16, 17 |
BIB_343 | EMA — Clinical Trials Information System (CTIS) / EudraCT migration. | N/A | 16 |
BIB_344 | MELODY-1 — NCT06540391. | B | 16, 17 |
BIB_345 | AMBLor — commercial-stage update 2024–2026. | C | 06, 15, 16, 19b |
BIB_346 | INTerpath-001 — NCT05933577 UK sites verified. | A | 16, 17, 18, 19 |
BIB_347 | British Association of Dermatologists — Melanoma Stage 1B Patient Information Leaflet. | B | 02, 04, 05, 20, 22 |
BIB_348 | NHS England Clinical Commissioning Policy Proposition (April 2026) — Neoadjuvant followed by adjuvant pembrolizumab for Stage III macroscopic cutaneou | A | 17, 18, 19a |
BIB_349 | NHS Scotland Cancer Collaborative — Adjuvant melanoma stage IIB/IIC pathway. | A | 17, 18, 19a, 20 |
BIB_350 | SMC (Scottish Medicines Consortium) decisions May 2026 — no melanoma drug on docket. | A | 17, 18, 19a |
BIB_351 | Melanoma Focus Virtual Regional Meeting 2026 — 15 May 2026 (today, while this brief was being assembled). | A | 17, 18, 19 |
BIB_352 | Named Beatson West of Scotland melanoma medical oncologists (identified 2026-05-15 via Melanoma Focus 2026 program + Veeva CTV). | B | 19, 20, 22, 24 |
BIB_353 | Beatson West of Scotland Clinical Trials Unit profile via Veeva CTV. | B | 16, 17, 19 |
BIB_354 | AMBLor IB/IIA prognostic biomarker — UKCA-marked September 2024; on NHS market. | A | 01, 04, 05, 06, 15, 24 |
BIB_355 | NICE Draft Guidance December 2025 — DRAFT NOT recommend lifileucel for previously treated unresectable/metastatic melanoma. | A | 17, 18, 19a |
BIB_356 | INTerpath-001 Phase III FULLY ENROLLED — Moderna/Merck announcement 20 January 2026. | B | 17, 18, 19a |
BIB_357 | Daromun Phase III in resectable Stage IIIB/C cutaneous melanoma. | A | 17, 18, 19a, 19b |
BIB_358 | DERM (Skin Analytics) — AI dermatoscopy AIaMD; NHS deployment 2026 state. | A | 05, 05a, 17 |
BIB_359 | Replimune RP1 (vusolimogene oderparepvec) — FDA double-rejection in advanced melanoma; April 2026. | A | 17, 18, 19a |
BIB_360 | ctDNA (Signatera) in Stage III melanoma neoadjuvant setting — mixed evidence; 2026 update. | B | 15, 17, 24 |
BIB_361 | MRA (Melanoma Research Alliance) 2026 grants — $18.4M global investment; landscape view of next-generation melanoma research. | A | 17, 19b, 22a |
BIB_362 | FMT (Fecal Microbiota Transplant) + immunotherapy in melanoma — 2026 maturation; three Phase 2 trials Nat Med January 2026. | A | 10, 17, 18, 19a |
BIB_363 | WoSCAN Skin Cancer MCN Workplan 2025-26 (April 2025) + Scottish Cancer Action Plan 2023-2026 Progress Report 2. | B | 17, 18, 19a, 20 |
BIB_364 | Vitamin D + immunotherapy / vitamin D + melanoma — two 2025–2026 meta-analyses; signal is for the IO subset, not for vitamin D supplementation alone a | B | 9, 10, 17, 18 |
BIB_365 | AJCC Version 9 + UICC TNM 9th edition (2025–2026) — melanoma STILL on AJCC 8th edition; staging citation BIB001 remains current and operative for this | A | 1, 2, 5, 17 |
BIB_366 | KEYNOTE-716 secondary analysis: adjuvant pembrolizumab REDUCES non-melanoma skin cancer but does NOT reduce new primary melanoma (Stage IIB/IIC, n=976 | A | 5, 5a, 7, 17, 19a |
BIB_367 | Varey 2026 Lancet Oncology SLNB meta-analysis — SLNB associated with REDUCED melanoma-specific mortality + REDUCED recurrence (HR 0.86 + HR 0.71); n=4 | A | 4, 5, 6, 7, 17, 24 |
BIB_368 | 🟡 Nicotinamide chemoprevention — Tan & Williams 2026 critical appraisal: "the jury was out and still is" — DOWNGRADES the brief's framing of nicotina | A | 5a, 12, 17 |
BIB_369 | Perioperative nutritional interventions — Sartini 2026 systematic review + meta-analysis (n=39 studies, Frontiers in Nutrition): immunonutrition OR 0. | B | 10, 13, 15, 21 |
BIB_370 | Sun protection 2025 — Morriss & Scardamaglia practical guide (Aust Prescr Oct 2025) + MRA 2026 sunscreen-misinformation survey + Skin Cancer Foundatio | A | 5a, 8, 9, 17, 21 |
BIB_371 | Scar management — McCarty & Del Rosso JCAD evidence review + 2026 systematic review of combination keloid therapies. Patient-actionable framework for | B | 3, 8, 17, 21 |
BIB_372 | Ortiz-Brugués 2026 Cancers chemoprevention review CLOSES the aspirin question for melanoma — Yan RCT NEGATIVE; aspirin / NSAIDs not chemopreventive fo | A | 5a, 8, 12, 17, 21 |
BIB_373 | Physical activity and skin cancer survival — Picelli 2026 JEADV meta-analysis (n=7 studies; sHR 0.69 all-cause mortality; sHR 0.57 post-diagnosis) UPG | B | 11, 12, 17, 21 |
BIB_374 | GLP-1 receptor agonists and melanoma/skin-cancer risk — 2024–2025 evidence synthesis: semaglutide REASSURING (HR 0.96 melanoma in UK CPRD; neutral in | B | 11, 12, 21, 24 |
BIB_375 | Obstructive sleep apnea (OSA) and melanoma prognosis — Gómez-Olivas 2023 CHEST prospective multicenter study (n=443): untreated moderate OSA aHR 2.45 | B | 11, 13a, 21, 24 |
BIB_376 | KEYNOTE-054 / EORTC1325 7-year analysis — adjuvant pembrolizumab vs placebo in resected Stage III melanoma: RFS HR 0.63 (50% vs 36% at 7yr); DMFS HR 0 | A | 17, 18, 19b |
BIB_377 | Chronotherapy of immune checkpoint inhibitors (ICI) — time-of-day scheduling affects melanoma and pan-cancer survival. Primary melanoma-specific evide | B | 17, 18, 24 |
BIB_378 | Alcohol consumption and cutaneous melanoma risk — evidence synthesis 2023–2025: NIH-AARP 2025 prospective (n=469,828; HR 1.17 for >3 drinks/day; MM HR | B | 10, 11, 13a, 21 |
BIB_379 | Antihypertensive medications and melanoma risk + RAAS inhibitors during ICI — evidence synthesis 2023–2024: Cohen 2024 JID Innov meta-analysis (42 stu | B | 13a, 18, 24 |
BIB_380 | AMBLor (AMBRA1 + loricrin IHC) — validated prognostic biomarker for non-ulcerated AJCC Stage I/II cutaneous melanoma: Lovat 2024 BJD n=840 multi-cohor | B | 15, 24 |
BIB_381 | Sedentary behavior and cancer/skin-cancer survivor mortality — evidence upgrade for TASK11 §3.1: Cao 2022 JAMA Oncology (n=1,535 cancer survivors; sit | B | 11, 21 |
BIB_382 | Adjuvant pembrolizumab at Stage IIB/IIC melanoma — NMSC-protective effect (KEYNOTE-716 secondary analysis, Leachman 2026 JAMA Netw Open, n=976): total | A | 05a, 17, 18, 19a |
BIB_383 | Melanoma surveillance after WLE — evidence synthesis 2025: Soyer/Janda 2025 JAMA Dermatology RCT (PMID 40136310, n=314) shows 3D total-body photograph | A | 05, 07, 17, 24 |
BIB_384 | NICE GID-TA10752 (Lifileucel) — timeline RECONCILIATION verified 2026-05-16 via prod rag-browser (default corpus, fetchandindex of live NICE page). | A | 17, 18, 19a |
BIB_385 | Adjuvant combination checkpoint intensification DOES NOT IMPROVE outcomes over anti-PD-1 monotherapy in resected melanoma — two major negative Phase 3 | A | 17, 18, 19a |
BIB_386 | SIGN 146 (Cutaneous Melanoma) — MARCH 2025 REVISION identified (brief likely cites the August 2023 version; one revision stale). | A | 2, 4, 5, 17, 19a |
BIB_387 | Adjuvant BRAF/MEK targeted therapy in resected melanoma — two-trial landscape update: (1) COLUMBUS-AD primary analysis (EORTC-2139-MG, ASCO 2025 LBA95 | A | 15, 17, 18 |
BIB_388 | 🟢 Lo SN et al. 2024/2025 JAMA Dermatology — the 0.8 mm Breslow threshold DOUBLES 20-year melanoma-death risk; DIRECTLY patient-specific (this patient | A | 1, 6, 23, 25 |
BIB_389 | Perrier et al. 2025 Int J Cancer (NOWAC) — pre-diagnosis physical activity reduces OVERALL + OTHER-CAUSE mortality in melanoma patients, but NOT signi | B | 11, 23, 25 |
BIB_390 | 🟢 Ni et al. 2026 Am J Epidemiol (MIA / University of Sydney) — absolute risk of 2nd primary cancer after 1st melanoma: 5-yr 2nd-primary-MELANOMA risk | A | 5, 7, 14, 23, 24 |
BIB_391 | Li et al. 2026 (J Med Internet Res / PMC13102330) — scoping review of ALL psychological FCR interventions across cancers. Two genuinely additive point | B | 20, 22, 25 |
BIB_392 | MelMarT-II (NCT03860883) STATUS UPDATE — CLOSED to recruitment 28 Aug 2025, fully accrued n=3000 internationally (UK 626); + Pospyelova 2025 meta-anal | A | 2, 3, 16, 22, 24 |
BIB_393 | Chang et al. 2026 JNCCN — GLP-1 / dual agonists and skin-cancer incidence: RCT meta-analysis (15 RCTs, n=73,412) shows NO significant effect on melano | B | 11, 12, 25 |
BIB_394 | McKechnie et al. 2024 Melanoma Res — statins & melanoma survival meta-analysis: non-significant 13% 5-yr OS benefit point estimate (HR 0.87, 95% CI 0. | C | 12, 25 |
BIB_395 | 🟢 ViDMe trial (De Smedt 2024 Br J Dermatol) — the DEFINITIVE melanoma-specific RCT on vitamin D supplementation: high-dose VD is SAFE but does NOT im | A | 9, 13, 25 |
BIB_396 | Tan SX, Muller NM, Zhou C (Univ Queensland / Princess Alexandra Hospital, 2024 JAAD Int) — Modeling study: existing prognostic markers can identify St | C | 5a, 15, 17, 18 |
BIB_397 | de Souza Carvalho et al. 2026 ASCO Educational Book — "Beyond Routine Surveillance Imaging for Melanoma": authoritative 2026 synthesis confirming NO r | A | 5, 6, 15, 17, 23 |
BIB_398 | Gilaberte Y, Ederra-Galé A, García-Alfonso JJ, Gracia-Cazaña T (2026 Cancers) — "Photoprotection for Skin Cancer: What's New": 2026 narrative review c | B | 8, 12, 13, 21 |
BIB_399 | APDSAS 2025 — Antibiotic Prophylaxis in Dermatologic Surgery Advisory Statement (Campbell, Virk, Lessard, Lohman, Otley; Mayo Clinic, Dermatol Surg, o | A | 3, 21, 24 |
BIB_400 | 🟢 Friedman, Williams, Lo, Thompson 2024 EClinicalMedicine — definitive melanoma-specific smoking-OUTCOMES meta-analysis (46 studies, n=164,166; MIA/S | A | 10, 11, 21, 24, 25, 5a |
BIB_401 | Polypodium leucotomos extract (PLE) — evidence-check of the cloud-loop BIB398 "ADD PLE" proposal: surrogate-endpoint photoprotection RCT data is consi | B | 8, 12 |
BIB_402 | Night-shift work & melanoma — large prospective NULL closes a plausible patient worry: circadian/sleep disruption does NOT raise melanoma risk. Patien | A | 5a, 25 |
BIB_403 | ctDNA/MRD in resected melanoma — NEW 2026 pooled meta-analysis quantifies the diagnostic-performance CEILING: high specificity (~94–96%) but LOW sensi | A | 5, 6, 17, 24, 24a |
BIB_404 | Socioeconomic deprivation → thicker melanoma at diagnosis (adjusted OR 1.65) — fills a genuine evidence GAP: the brief has the patient's refugee/housi | B | 21, 24, 25 |
BIB_405 | i31-GEP-for-SLNB prospective DECIDE trial (Guenther 2025) — evidence-check of the GEP-to-forego-SLNB use case in a cohort whose MEDIAN Breslow is 0.8 | B | 4, 15, 24 |
BIB_406 | 🟢 Aebischer/Leiter 2025 (German Central Malignant Melanoma Registry, n=12,132) — the empirical hazard-rate-by-thickness-band evidence that ANCHORS th | A | 5, 7, 24, 25 |
BIB_407 | Alexander/Chen 2026 JAAD (Washington Univ St. Louis, n=1491) — empirical interobserver-variability evidence that ANCHORS the brief's pre-stated specia | A | 1, 19, 24, 24a |
BIB_408 | Laiouar-Pedari 2026 JAMA Dermatology (DKFZ Heidelberg) — prospective-only meta-analysis quantifying AI-assisted dermoscopy for melanoma: ANCHORS the b | A | 5, 17, 22a |
BIB_409 | Aduse-Poku 2025 — RCT-only meta-analysis of smoking-cessation interventions in cancer patients: OPERATIONALISES BIB400's flagged "if smoker, cessation | A | 10, 11, 21, 24, 25 |
BIB_410 | Benesch & Skitzki 2024 Melanoma Res (Roswell Park) — anaesthetic MODALITY (general vs local/regional) and melanoma-specific outcomes via peri-operativ | C | 21, 24, 25 |
BIB_411 | Creatine in oncology — evidence anchor for TASK28 (patient asked to focus on creatine). Bottom line: creatine monohydrate is one of the best-evidenced | B | 11, 13, 13a, 26, 28 |
BIB_412 | Fasting / fasting-mimicking diet (FMD) / ketogenic / caloric restriction in cancer — evidence anchor for TASK31 (patient asked to split fasting into a | D | 10, 13a, 26, 31 |
BIB_413 | Ageing / "age reversal" ↔ cancer — evidence anchor for TASK34 (patient asked re age-reversal & cancer; family has AI/longevity interest). Bottom line: | D | 22a, 25, 26, 34 |
BIB_414 | Telomerase / telomere length & melanoma — evidence anchor for TASK35 (patient asked re telomerase; family longevity interest). The decisive, counter-i | A | 15, 22a, 32, 34, 35 |
BIB_415 | Selenium & skin-cancer — Filippini/Vinceti 2025 J Trace Elem Med Biol meta-analysis: fills a REAL GAP (zero prior selenium content in the brief despit | B | 5a, 10, 13, 13a, 26 |
BIB_416 | Polyphenols (green tea/EGCG, resveratrol, curcumin) for skin-cancer chemoprevention — extracts the UNCAPTURED polyphenol arm of the already-cited Orti | D | 12, 26, 33, 34 |
BIB_417 | Physical activity & survival in melanoma survivors — convergent 2025-26 evidence that the exercise mortality benefit in melanoma patients operates PRI | B | 11, 21, 25, 26 |
BIB_418 | Psychological distress / mental-health disorders in (early) melanoma & cancer outcomes — empirically ANCHORS the brief's qualitative TASK22 psychosoci | A | 22, 24, 25 |
BIB_419 | Ultra-processed food (UPF) & cancer-survivor mortality — fills a real GAP (no prior UPF entry; only a passing "low ultra-processed" mention in TASK26 | B | 10, 25, 26 |
BIB_420 | Pathology-report COMPLETENESS (synoptic/structured vs narrative) — fills a real GAP and is TIME-CRITICAL: the 2026-05-26 WLE report drives the ENTIRE | A | 1, 15, 24, 24a |
BIB_421 | Timing of definitive (wide-local-excision) surgery after melanoma diagnosis — fills a GENUINE, EXACTLY-PATIENT-SPECIFIC, TIME-CRITICAL GAP: the patien | B | 3, 24, 24a |
BIB_422 | Post-WLE scar management and peri-operative wound-healing nutrition — TIME-CRITICAL protocol (surgery 2026-05-26, 9 days); fills the TASK21 §21.9 gap | A | 13a, 21, 24 |
BIB_423 | The MIA Sentinel-Node-Metastasis Risk model in thin (<1.0 mm) melanoma — national-utilisation evidence that DIRECTLY supports asking for an explicit c | A | 5a, 15, 24, 24a |
BIB_424 | Dermatologic screening + method → Breslow thickness at diagnosis: the evidence that reframes this patient's LIFELONG second-primary surveillance (TASK | B | 5, 5a, 8b, 14 |
BIB_425 | CHALLENGE trial (NEJM 2025) + Irwin editorial — FIRST RCT to prove structured exercise improves cancer DFS and OS after curative-intent treatment: DFS | A | 11, 17, 18, 21 |
BIB_426 | T1 (thin, ≤1.0 mm) melanoma patients have OVERALL survival SIMILAR TO OR BETTER THAN the matched general population — the most powerfully reassuring p | A | 22, 22a, 23, 25, 26 |
BIB_427 | Citrus / dietary furocoumarin & cutaneous-melanoma risk — fills a ZERO-coverage gap (coffee=BIB124, SSB=BIB125, antioxidants=BIB128 were covered; citr | C | 8, 10, 22, 22a, 26 |
BIB_428 | Truncal melanoma has VARIABLE, MULTI-DIRECTIONAL lymphatic drainage — directly patient-site-specific (his primary is flank / lower trunk): if he is ev | B | 4, 24, 24a |
BIB_429 | EADO 2024 European consensus-based melanoma guideline — Part 2: Treatment (PMID 39709737) — ZERO-COVERAGE GAP: BIB330 covers Part 1 Diagnostics only; | A | 2, 4, 5, 24 |
BIB_430 | Sunscreen-safety controversy (chemical-filter systemic absorption / endocrine concern) — evidence-anchored counter-misinformation literacy. Fills a ZE | B | 8, 22a |
BIB_431 | Cannabis / cannabinoids (CBD/THC) & cancer immunotherapy — evidence-anchored, ANTI-ALARMIST literacy. Fills a real gap: cannabinoids are discussed in | C | 11, 12, 22a |
BIB_432 | Professional medical interpreter & health-literacy-concordant communication at the surgical/oncology consult — fills a real gap (no prior dedicated en | A | 22, 24, 24a, 25 |
BIB_433 | Post-operative complication rates & risk factors for minor cutaneous excision under local anaesthesia — REFINES TASK03 §143 from a vague qualitative " | B | 3, 21, 22, 24 |
BIB_434 | ACE inhibitor / ramipril on the morning of surgery — hold or continue? Evidence synthesis 2024–2025 — FILLS AN ABSENT GAP IN TASK13a/TASK24: the peri- | A | 13a, 24, BRIEF §4.6 |
BIB_435 | Wearable UV dosimeter / UV-index-app feedback as a photoprotection ADHERENCE tool — fills a ZERO-coverage gap and targets THIS patient's actual defici | C | 8, 22a |
BIB_436 | Melatonin & melanoma — the CALIBRATED "permitted for sleep, NOT for cancer" supplement entry. Fills a ZERO-coverage gap (only incidental in BIB375/OSA | C | 13a, 22, 22a |
BIB_437 | Financial / time toxicity → cost-related nonadherence → worse outcomes — fills a ZERO-coverage gap and supplies the MECHANISTIC BRIDGE the access-equi | C | 22, 24, 25 |
BIB_438 | Obesity paradox in melanoma immunotherapy + body composition → ICI outcomes: BMI 30.4 is NOT a contingency liability — fills a ZERO-coverage gap. The | B | 11, 18 |
BIB_439 | "Number needed to excise" / benign:malignant excision ratio — anti-FCR EXPECTATION-SETTING literacy. Fills a ZERO-coverage gap (NNE/benign-ratio frami | B | 7, 22, 24a |
BIB_440 | IO102-IO103 (IDO1 + PD-L1 fixed cancer vaccine) + pembrolizumab — first Phase 3 cancer vaccine trial in first-line advanced cutaneous melanoma (IOB-01 | B | 17, 18, 24 |
BIB_441 | Omega-3 (marine n-3 PUFA / fish oil) & melanoma — the CALIBRATED "fine for cardiovascular/competing-risk, NOT a melanoma measure" supplement entry. Fi | C | 10, 13a, 22a, 26 |
BIB_442 | "I need sun for vitamin D" — the single most common photoprotection-ADHERENCE-ERODING belief, refuted with a consolidated, primary-anchored, patient-f | A | 8, 22a, 25 |
BIB_443 | Whole-body MRI / total-body "executive-health" imaging for a Stage IB melanoma patient — the OVER-TESTING counter-pressure entry (sibling to the welln | A | 5, 17, 22, 22a |
BIB_444 | Epinephrine (adrenaline) in local anaesthetic for hypertensive patients undergoing skin surgery — fills a ZERO-coverage gap in the brief: neither BIB2 | B | 3, 13a, 24 |
BIB_445 | Dysplastic naevus re-excision decision rule — completely-excised mild/moderately (and per new evidence, even severely) dysplastic naevi with CLEAR mar | B | 7, 22, 24 |
BIB_446 | Non-pharmacological blood pressure reduction in the acute pre-operative window — evidence-graded lifestyle actions to support threshold-crossing below | B | 13a, 24 |
BIB_447 | Initial diagnostic-biopsy MODALITY → Breslow microstaging accuracy / residual tumour at WLE — the MECHANISM behind the TASK24a DT-03 upstage-probabili | B | 22, 24, 24a |
BIB_448 | Post-WLE analgesia for a patient on ramipril — NSAIDs are CONTRAINDICATED (dual-whammy AKI mechanism); paracetamol 1 g QDS is the safe, evidence-suppo | A | 13a, 21, 24 |
BIB_449 | KEYVIBE-010 (TIGIT inhibitor vibostolimab + pembrolizumab vs pembrolizumab alone as adjuvant therapy for resected Stage IIB–IV melanoma) — NEGATIVE Ph | A | 17, 18, 19a |
BIB_450 | Dietary FIBER (high intake → better anti-PD-1 outcomes) and commercial PROBIOTIC SUPPLEMENTS (signal toward WORSE ICI response) in melanoma — the pati | B | 10, 12, 18, 22a, 26 |
BIB_451 | Metformin & melanoma — 2024 systematic review + meta-analysis (Feng et al., Frontiers in Oncology) + supporting cohort evidence: CALIBRATED assessment | B | 10, 22a |
BIB_452 | Sex differences in melanoma IMMUNOTHERAPY (anti-PD-1/CTLA-4) efficacy & toxicity — contingency literacy ONLY; fills a ZERO-coverage gap and is distinc | C | 18, 22a, 23 |